Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 extension study of once-weekly lonapegsomatropin in adults with growth hormone deficiency
MOH_2023-04-04_012511Phase 3Not yet recruiting
- Sponsor
- Ascendis Pharma
- Start
- Apr 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lonapegsomatropin in adult onset growth hormone deficiency (AGHD), sponsored by Ascendis Pharma. Primary endpoint: Long-term safety. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
lonapegsomatropin
03
Conditions
adult onset growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on MOH_2023-04-04_012511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-04_012511.